News | July 06, 2022
Wacker to expand mRNA-based actives capacity at Halle, Germany
Company is investing more than €100 million in the expansion of the Halle site
Company is investing more than €100 million in the expansion of the Halle site
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
The scope of supply includes the skid-mounted plant as well as on-site installation and commissioning support
The expansion makes Exothera one of the largest viral vector facilities in Europe
Data published in the prestigious journal ACS Central Science of the American Chemical Society
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Subscribe To Our Newsletter & Stay Updated
